October Pharma results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements.
Net profit41.71 millionEGP · +1.8% vs the same period a year earlier
Total assets1.02 billionEGP · +59.8% vs the same period a year earlier
Shareholders' equity449 millionEGP · +33.8% vs the same period a year earlier
Operating cash flow60.99 millionEGP · +323.4% vs the same period a year earlier
In short
- October Pharma's net profit for Q1 2023 was about 41.71 million EGP, up +1.8% from 40.97 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 1.02 billion EGP, and shareholders' equity about 449 million EGP.
- Operating cash flow for Q1 2023 was positive at 60.99 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit41.71 million40.97 million+1.8%
Gross profit115 million93.29 million+23.5%
Total assets1.02 billion638 million+59.8%
Total liabilities570 million302 million+88.6%
Shareholders' equity449 million336 million+33.8%
Total liabilities and equity1.02 billion638 million+59.8%
Operating cash flow60.99 million-27.3 million+323.4%
Investing cash flow-14.32 million-2.35 million−509.9%
Financing cash flow-26.2 million25.24 million−203.8%
Net change in cash20.47 million-4.4 million+565.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy